Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences' stock price has experienced significant fluctuations in the past six months. On May 5, 2026, the share price was $3.18, a 55.98% decline from $7.22 on May 6, 2025. Positive 12-month follow-up data from the Phase 2b CLOVER WaM study and an oversubscribed financing of up to $140 million led to a positive market reaction on May 5, 2026. A subset of the CLOVER WaM clinical trial data was accepted for presentation at the American Society of Clinical Oncology Conference 2026 on April 21, 2026. The first patient was enrolled in a Phase 1b clinical trial for CLR 125 on April 14, 2026. Cellectar reported its financial results for the year ended 2025 on March 4, 2026, highlighting regulatory progress for iopofosine I 131 and the initiation of the CLR 125 study.

As a clinical-stage biopharmaceutical company, Cellectar Biosciences, Inc. is primarily focused on the research, development, and clinical trials of its drug candidates rather than the commercial sale of approved products. Therefore, traditional concepts of demand seasonality are not directly applicable to Cellectar Biosciences. The demand for their investigational drugs is driven by the progression of clinical trials, regulatory milestones, and the unmet medical needs in the oncology space.

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical and radiopharmaceutical company focused on discovering, developing, and commercializing cancer treatments. The company's core strategy involves its Phospholipid Drug Conjugate (PDC™) delivery platform, which selectively targets cancer cells. The company's lead PDC candidate, Iopofosine I 131 (CLR 131), is in Phase 2 clinical studies for various B-cell malignancies and has received multiple designations from the FDA and EMA. Other product candidates include CLR 125 for solid tumors, CLR 225 targeting solid tumors like pancreatic cancer, CLR 124 for tumor detection, and CLR 1502 for intraoperative tumor imaging. Cellectar also engages in research and development collaborations to advance its PDC platform.

Cellectar Biosciences, Inc. is headquartered in Florham Park, New Jersey, United States. The company's focus for drug development and commercialization is primarily within the United States.

Cellectar Biosciences' reputation has been primarily influenced by its clinical and corporate progress in developing cancer therapies. Positive developments, such as the reporting of durable responses and efficacy from the Phase 2b CLOVER WaM study for iopofosine I 131, the successful oversubscribed financing round, and the initiation of new clinical trials, contribute positively to the company's standing. The company emphasizes its mission to develop targeted cancer therapies using its proprietary platform to precisely treat tumors while minimizing harm to healthy tissue.

Cellectar Biosciences, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 16.41% of the company's stock is owned by institutional investors, and insiders hold about 5.04% of the stock. Major institutional owners and shareholders include Bleichroeder LP, Vanguard Group Inc, DRW Securities, LLC, and others.